Netflix is the first of the major technology companies to report its quarterly results on Tuesday.

Get ready for a crazy next 3 weeks, including these heavyweights:

Intuitive Surgical: $ISRG (+0,47 %)

LVMH: $MC (+0,01 %)

Meta: $META (+0,57 %)

Tesla: $TSLA (+1,22 %)

Microsoft: $MSFT (+1,42 %)

Fair Isaac: $FICO (+0,37 %)

Amazon: $AMZN (+0,33 %)

Palantir: $PLTR (+3,28 %)

Spotify: $SPOT (+0,53 %)

AMD: $AMD (+0,98 %)

Novo Nordisk: $NOVO B (+0,78 %)

Who do you have your eye on in particular?

$NOVO B (+0,78 %) had been on my watch list for some time.

After the setback of the last few weeks, I have now added a first position to my portfolio.

Even if the hype surrounding the well-known weight loss injections could slowly level off or lose momentum, I am of the opinion that Novo Nordisk is a good choice in the health sector.

The predominantly unhealthy Western diet boosts the business model and allows Novo Nordisk to swim in money through the sale of its insulin preparations alone.

If the share price falls further, I will definitely buy more here.

I have bought more.

74,60€ , 11 pieces

Now my new buy-in is €79.90.

Previously my buy-in was €83.57

Now it can go up again for all I care.

According to ChatGPT:

Novo Nordisk's patents for its drugs and technologies vary by product and region. A significant example is semaglutide, the active ingredient in drugs such as Ozempic and Wegovy. In China, the patent for semaglutide expires in 2026, allowing the introduction of generics in this market. In Europe and Japan, however, patent protection will remain in place until 2031, and in the USA until 2032.

For other Novo Nordisk medicines, such as Xultophy, Tresiba and Ryzodeg, patent protection in Europe runs until 2028 and 2029 respectively, while patent protection for many of the company's other products does not expire until after 2031.

It is important to note that the exact patent terms may vary depending on the country and specific product. The above dates provide a general overview of Novo Nordisk's most important patents.

Let's see what happens.

To the people who are so hot on $NOVO B (+0,78 %) I'm interested in what your short, medium and long-term thesis is.

Do you know that the Ozempic patent is only for this year? At least I keep seeing people on the timeline who seem to be quite new to the subject and I wonder if there is any knowledge at all about the patent situation.

With Ozempic, the mainstay will break away and the company is anything but favorably valued.

How do you rate the rapidly growing competition and the pipeline?

$NOVO B (+0,78 %) should you leave the sinking ship or stay on it?

$NOVO B (+0,78 %) increased the Novo position by 90 shares today. Now it should go up again soon

$NOVO B (+0,78 %) where very you the end? Thinking about buying 🤔

$NOVO B (+0,78 %)

I decided to buy today.

Even if I believe that it could still go down to €70 (there are also analysts who see €68.

Why today: Resistance from August 23 was reached today. I hope that this will now become support. If not, the share will form a bottom at around €70.

I have set a stop at €65.

Fingers crossed 🤞

$NOVO B (+0,78 %) I like the weekly chart relatively well, the 200 is directly below us and the RSI is also oversold.

Contra: Earnings in two weeks.

I got in here, KO: 15 crowns below the last low